MXPA02005236A - Metodos de tratamiento de lupus con base en la afinidad de anticuerpos y metodos de separacion por exclusion y composiciones para el uso de los mismos. - Google Patents
Metodos de tratamiento de lupus con base en la afinidad de anticuerpos y metodos de separacion por exclusion y composiciones para el uso de los mismos.Info
- Publication number
- MXPA02005236A MXPA02005236A MXPA02005236A MXPA02005236A MXPA02005236A MX PA02005236 A MXPA02005236 A MX PA02005236A MX PA02005236 A MXPA02005236 A MX PA02005236A MX PA02005236 A MXPA02005236 A MX PA02005236A MX PA02005236 A MXPA02005236 A MX PA02005236A
- Authority
- MX
- Mexico
- Prior art keywords
- antibodies
- treatment
- exclusion
- affinity
- compositions
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Urology & Nephrology (AREA)
- Peptides Or Proteins (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US16771699P | 1999-11-28 | 1999-11-28 | |
| PCT/US2000/042307 WO2001041813A2 (en) | 1999-11-28 | 2000-11-28 | Methods of treating lupus based on antibody affinity and screening methods and compositions for use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MXPA02005236A true MXPA02005236A (es) | 2004-03-19 |
Family
ID=22608518
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MXPA02005236A MXPA02005236A (es) | 1999-11-28 | 2000-11-28 | Metodos de tratamiento de lupus con base en la afinidad de anticuerpos y metodos de separacion por exclusion y composiciones para el uso de los mismos. |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US7081242B1 (https=) |
| EP (1) | EP1233791A2 (https=) |
| JP (1) | JP2003516526A (https=) |
| KR (1) | KR20020059808A (https=) |
| CN (2) | CN1399562A (https=) |
| AU (1) | AU783282C (https=) |
| CA (1) | CA2391944A1 (https=) |
| HK (1) | HK1045944A1 (https=) |
| MX (1) | MXPA02005236A (https=) |
| NO (1) | NO20022441L (https=) |
| WO (1) | WO2001041813A2 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6858210B1 (en) | 1998-06-09 | 2005-02-22 | La Jolla Pharmaceutical Co. | Therapeutic and diagnostic domain 1 β2GPI polypeptides and methods of using same |
| HK1045944A1 (zh) | 1999-11-28 | 2002-12-20 | La Jolla Pharmaceutical Company | 基於抗体亲和力的狼疮治疗方法和筛选方法及用於其的组合物 |
| US20030114405A1 (en) * | 2001-08-13 | 2003-06-19 | Linnik Matthew D. | Methods of treating systemic lupus erythematosus in individuals having significantly impaired renal function |
| AU2003303524A1 (en) * | 2002-12-27 | 2004-07-29 | La Jolla Pharmaceutical Company | Methods of improving health-related quality of life in individuals with systemic lupus erythematosus |
| US20040258683A1 (en) * | 2003-03-30 | 2004-12-23 | Linnik Matthew D. | Methods of treating and monitoring systemic lupus erythematosus in individuals |
| US20060229270A1 (en) * | 2005-03-10 | 2006-10-12 | La Jolla Pharmaceutical Company | Methods of treating proteinuria by reducing double-stranded DNA antibodies |
| WO2009052415A1 (en) * | 2007-10-17 | 2009-04-23 | The Regents Of The University Of California | Peptide for the induction of immune tolerance as treatment for systemic lupus erythematosus |
| CN102477079A (zh) * | 2010-11-24 | 2012-05-30 | 中国人民解放军军事医学科学院基础医学研究所 | 一种新型多肽在系统性红斑狼疮诊断中的应用 |
| WO2012116210A2 (en) * | 2011-02-23 | 2012-08-30 | The Regents Of The University Of California | Peptide for the induction of immune tolerance as treatment for systemic lupus erythematosus |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5126131A (en) | 1983-01-24 | 1992-06-30 | The Johns Hopkins University | Therapeutic suppression of specific immune responses by administration of antigen-competitive conjugates. |
| US6022544A (en) | 1983-01-24 | 2000-02-08 | The John Hopkins University | Therapeutic suppression of specific immune responses by administration of oligomeric forms of antigen of controlled chemistry |
| US5370871A (en) | 1983-01-24 | 1994-12-06 | The Johns Hopkins University | Therapeutic suppression of specific immune responses by administration of oligomeric forms of antigen of controlled chemistry |
| US5162515A (en) | 1990-01-16 | 1992-11-10 | La Jolla Pharmaceutical Company | Conjugates of biologically stable polymers and polynucleotides for treating systemic lupus erythematosus |
| US5391785A (en) | 1990-01-16 | 1995-02-21 | La Jolla Pharmaceutial Company | Intermediates for providing functional groups on the 5' end of oligonucleotides |
| US5552391A (en) | 1990-01-16 | 1996-09-03 | La Jolla Pharmaceutical Company | Chemically-defined non-polymeric valency platform molecules and conjugates thereof |
| US5268454A (en) | 1991-02-08 | 1993-12-07 | La Jolla Pharmaceutical Company | Composition for inducing humoral anergy to an immunogen comprising a t cell epitope-deficient analog of the immunogen conjugated to a nonimmunogenic carrier |
| AU8869291A (en) | 1990-10-04 | 1992-04-28 | University Of Virginia Alumni Patents Foundation, The | Primate erythrocyte bound monoclonal antibody heteropolymers |
| IE922292A1 (en) | 1991-07-15 | 1993-01-27 | Jolla Pharma | Modified phosphorous intermediates for providing functional¹groups on the 5' end of oligonucleotides |
| EP1808183A3 (en) | 1993-09-08 | 2009-07-01 | La Jolla Pharmaceutical Company | Chemically-defined non-polymeric valency platform molecules and conjugates thereof |
| KR100361933B1 (ko) | 1993-09-08 | 2003-02-14 | 라 졸라 파마슈티칼 컴파니 | 화학적으로정의된비중합성결합가플랫폼분자및그것의콘주게이트 |
| CA2183535A1 (en) | 1994-02-28 | 1995-08-31 | Ronald P. Taylor | Antigen-based heteropolymers and method for treating autoimmune diseases using the same |
| US5874409A (en) | 1995-06-07 | 1999-02-23 | La Jolla Pharmaceutical Company | APL immunoreactive peptides, conjugates thereof and methods of treatment for APL antibody-mediated pathologies |
| US5856464A (en) | 1995-06-07 | 1999-01-05 | Lajolla Pharmaceutical Company | Selective capping solution phase oligonucleotide synthesis |
| US5817752A (en) | 1996-06-06 | 1998-10-06 | La Jolla Pharmaceutical Company | Cyclic polypeptides comprising a thioether linkage and methods for their preparation |
| KR20000016414A (ko) | 1996-06-06 | 2000-03-25 | 와이즈먼 앤드루 | Apl 면역반응성 펩티드, 그것의 콘주게이트 및 apl항체-매개병변의 치료방법 |
| WO1998046523A1 (en) | 1997-04-11 | 1998-10-22 | Chiyoda Corporation | Catalyst for preparation of synthesis gas and process for preparing carbon monoxide |
| EP1965213A3 (en) | 1998-02-04 | 2009-07-15 | Invitrogen Corporation | Microarrays and uses therefor |
| DK1411075T3 (da) | 1998-03-12 | 2008-10-27 | Nektar Therapeutics Al Corp | Fremgangsmåde til fremstilling af polymerkonjugater |
| US6858210B1 (en) | 1998-06-09 | 2005-02-22 | La Jolla Pharmaceutical Co. | Therapeutic and diagnostic domain 1 β2GPI polypeptides and methods of using same |
| MXPA01002580A (es) | 1998-09-10 | 2002-04-08 | Univ Virginia | Anticuerpos para c3b(1) para el suministro de agentes de diagnostico y terapeuticos para celulas cancerosas. |
| US6572856B1 (en) | 1998-09-10 | 2003-06-03 | The University Of Virginia Patent Foundation | Methods for the prevention and treatment of cancer using anti-C3b(i) antibodies |
| JP2002531531A (ja) | 1998-12-09 | 2002-09-24 | ラ ホヤ ファーマシューティカル カンパニー | 循環している抗体を減少させるための方法および処方物 |
| US6458953B1 (en) | 1998-12-09 | 2002-10-01 | La Jolla Pharmaceutical Company | Valency platform molecules comprising carbamate linkages |
| US6399578B1 (en) | 1998-12-09 | 2002-06-04 | La Jolla Pharmaceutical Company | Conjugates comprising galactose α1,3 galactosyl epitopes and methods of using same |
| US20010010818A1 (en) | 1998-12-09 | 2001-08-02 | Engle Steven B. | Methods and formulations for reducing circulating antibodies |
| KR20020022691A (ko) | 1999-06-08 | 2002-03-27 | 와이즈먼 앤드루 | 아미노옥시기를 포함하는 원자가 플랫폼 분자 |
| HK1045944A1 (zh) | 1999-11-28 | 2002-12-20 | La Jolla Pharmaceutical Company | 基於抗体亲和力的狼疮治疗方法和筛选方法及用於其的组合物 |
| AU2593901A (en) | 1999-12-23 | 2001-07-03 | Elusys Therapeutics, Inc. | Therapeutic use of particles displaying pathogen-specific binding moieties |
| EP1284752A4 (en) | 2000-04-26 | 2004-08-18 | Elusys Therapeutics Inc | BISPECIFIC MOLECULES AND USES THEREOF |
| CN1434726A (zh) | 2000-06-08 | 2003-08-06 | 拉卓拉药物公司 | 包含高分子量聚环氧乙烷的多价平台分子 |
| AU4155602A (en) | 2000-11-01 | 2002-06-18 | Elusys Therapeutics Inc | Method of producing biospecific molecules by protein trans-splicing |
| JP2004529945A (ja) | 2001-05-17 | 2004-09-30 | ラ ホヤ ファーマシューティカル カンパニー | Ｃｄ２１を阻害する薬剤を使用して抗体媒介性病理を処置する方法 |
| US20030114405A1 (en) | 2001-08-13 | 2003-06-19 | Linnik Matthew D. | Methods of treating systemic lupus erythematosus in individuals having significantly impaired renal function |
| AU2003303524A1 (en) | 2002-12-27 | 2004-07-29 | La Jolla Pharmaceutical Company | Methods of improving health-related quality of life in individuals with systemic lupus erythematosus |
| US20040258683A1 (en) | 2003-03-30 | 2004-12-23 | Linnik Matthew D. | Methods of treating and monitoring systemic lupus erythematosus in individuals |
-
2000
- 2000-11-28 HK HK02107393.6A patent/HK1045944A1/zh unknown
- 2000-11-28 WO PCT/US2000/042307 patent/WO2001041813A2/en not_active Ceased
- 2000-11-28 EP EP00992252A patent/EP1233791A2/en not_active Withdrawn
- 2000-11-28 KR KR1020027006803A patent/KR20020059808A/ko not_active Ceased
- 2000-11-28 US US09/724,822 patent/US7081242B1/en not_active Expired - Fee Related
- 2000-11-28 CN CN00816224A patent/CN1399562A/zh active Pending
- 2000-11-28 CN CNA2008101656741A patent/CN101422614A/zh active Pending
- 2000-11-28 CA CA002391944A patent/CA2391944A1/en not_active Abandoned
- 2000-11-28 JP JP2001543157A patent/JP2003516526A/ja active Pending
- 2000-11-28 AU AU39702/01A patent/AU783282C/en not_active Ceased
- 2000-11-28 MX MXPA02005236A patent/MXPA02005236A/es active IP Right Grant
-
2002
- 2002-05-23 NO NO20022441A patent/NO20022441L/no not_active Application Discontinuation
-
2005
- 2005-03-15 US US11/081,309 patent/US20060142229A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2001041813A3 (en) | 2002-01-03 |
| CA2391944A1 (en) | 2001-06-14 |
| CN1399562A (zh) | 2003-02-26 |
| JP2003516526A (ja) | 2003-05-13 |
| US20060142229A1 (en) | 2006-06-29 |
| AU3970201A (en) | 2001-06-18 |
| KR20020059808A (ko) | 2002-07-13 |
| US7081242B1 (en) | 2006-07-25 |
| CN101422614A (zh) | 2009-05-06 |
| EP1233791A2 (en) | 2002-08-28 |
| NO20022441D0 (no) | 2002-05-23 |
| WO2001041813A2 (en) | 2001-06-14 |
| HK1045944A1 (zh) | 2002-12-20 |
| AU783282B2 (en) | 2005-10-06 |
| AU783282C (en) | 2006-04-06 |
| NO20022441L (no) | 2002-07-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE196314T1 (de) | Verfahren und zusammensetzungen zur verhinderung von entzündungen und angiogenese enthaltend säugetieren cd97 alpha untereinheit | |
| CY1112993T1 (el) | Παραγοντες ειδικης δεσμευσης της αγγειοποιητινης-2 και της αγγειοποιητινης-1 | |
| BRPI0409133A (pt) | formulações farmacêuticas contendo metilnaltrexona | |
| HUP0401591A2 (hu) | Új receptor-nukleinsavak és- polipeptidek | |
| AR035977A1 (es) | Inmunoconjugados de anticuerpos cd44 citotoxicos. | |
| EA200300441A1 (ru) | Ассоциация антагониста рецептора св1 и сибутрамина, содержащие их фармацевтические композиции и их применение для лечения ожирения | |
| UY27943A1 (es) | Composiciones y mctodos para tratar el crncer usando inmunoconjugados de anticuerpo para cd44 citotnxicos y agentes quimioterapcuticos | |
| ES2100174T3 (es) | Nuevos anticuerpos reactivos con carcinomas humanos. | |
| BR9910327A (pt) | Anticorpo, uso de um anticorpo, sequência de dna codificando uma cadeia de anticorpo, e, formulação farmacêutica | |
| BRPI9917007B8 (pt) | azabicicloalcanos como moduladores de ccr5, composição farmacêutica contendo os mesmos, bem como seu uso | |
| EP1450857A4 (en) | NEUTRALIZING ANTIBODIES TO HIV WITH A WIDE CROSS-REACTION SELECTED BY ENV-CD4-CO RECEPTOR COMPLEXES | |
| IS6658A (is) | Ný efnasambönd | |
| CY1106366T1 (el) | Ενωση λακταμης για την αναστολη της απελευθερωσης ή της συνθεσης βητα-αμυλοειδους πεπτιδιου | |
| ATE383430T1 (de) | Rekombinante antikörper und immunkonjugate gezielt auf cd22-tragende zellen und tumoren | |
| PT1318791E (pt) | Composicao farmaceutica semi-solida de isotretinoina | |
| BRPI0414313A (pt) | inibidores de citocinas | |
| TR200002731T2 (tr) | Proteolitik antikorların indüktör ve inhibitörlerinin tanımlanması, kompozisyonları ve kullanımları için metotlar | |
| CY1110033T1 (el) | Τεχνητα ανθρωπινα θεραπευτικα αντισωματα εναντια σε ισομορφες cd45 | |
| SE0300119D0 (sv) | Novel compounds | |
| DE60143857D1 (de) | Zusammensetzung bestehend aus phy906 und chemotherapeutika | |
| DK1104425T3 (da) | Hidtil ukendte thiazolopyrimidinforbindelser | |
| NI200600290A (es) | Derivados de pirazol, composiciones que contienen dichos compuestos y procedimientos de uso | |
| PT1506185E (pt) | Compostos novos e sua utilizacao | |
| MXPA02005236A (es) | Metodos de tratamiento de lupus con base en la afinidad de anticuerpos y metodos de separacion por exclusion y composiciones para el uso de los mismos. | |
| IL176007A0 (en) | Antibodies specific to c35 and pharmaceutical compositions containing the same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |